Abstract
Summary
Soluble RANKL (sRANKL) and osteoprotegerin (OPG) are regulators of osteoclast differentiation and activation, but adequate pediatric reference values are lacking. Here we provide LMS (Lambda-Mu-Sigma)-based continuous pediatric reference percentiles for sRANKL, OPG and sRANKL/OPG ratio that will allow calculation of standardized patient z-scores to assess bone modeling in children.
Purpose
Soluble receptor activator of nuclear factor kappa B ligand (sRANKL) and osteoprotegerin (OPG) are regulators of osteoclast differentiation and activation and thus bone metabolic turnover in children. Adequate pediatric reference values for their serum/plasma concentrations are lacking. The development of Lambda-Mu-Sigma (LMS)-based continuous reference percentiles for laboratory parameters allow improved data interpretation in clinical practice.
Methods
A total of 300 children aged 0.1–18 years (166 boys) were enrolled in the HAnnover Reference values for Pediatrics (HARP) study. sRANKL and OPG were assessed by ELISA. LMS-based continuous reference percentiles were generated using RefCurv software.
Results
LMS-based percentiles were established for sRANKL, OPG and sRANKL/OPG ratio, which were all found to be age-dependent. sRANKL and sRANKL/OPG associated with sex. In boys, sRANKL percentiles were highest during infancy, followed by a continuous decline until the age of 7 years and a second peak around age 12–13 years. In girls, a continuous, slow decline of sRANKL percentiles was noticed from infancy onwards until the age of 13 years, followed by a rapid decline until adulthood. OPG percentiles continuously declined from infancy to adulthood. The percentiles for sRANKL/OPG ratio paralleled those of sRANKL. Serum concentrations of sRANKL correlated with OPG and serum phosphate z-scores, while OPG concentrations inversely associated with standardized body weight, BMI, and urinary phosphate to creatinine ratio (each p < 0.05).
Conclusion
This is the first report of LMS-based continuous pediatric reference percentiles for sRANKL, OPG and sRANKL/OPG ratio that allows calculation of standardized patient z-scores to assess bone metabolic turnover in children.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Osteoclastogenesis is tightly regulated by osteoblasts via the secretion of a receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG), to ensure adequate bone modeling in childhood and adolescence and thus achieve proper peak bone mass in young adulthood [1,2,3,4]. The binding of RANKL to its receptor RANK, expressed by osteoclast progenitor cells and dendritic cells, triggers the activation and differentiation of osteoclasts along with the prevention of their apoptosis, which causes resorption of newly formed bone allowing osteoblasts to lay down new bone, resulting in bone metabolic turnover [1, 2, 4]. RANKL exists in three forms: as a transmembrane protein expressed by osteoblasts and other cells of the mesenchymal lineage, as a soluble molecule released by enzymatic cleavage, and as a primary secreted form produced by activated T-lymphocytes [2]. OPG acts as a decoy receptor by blocking the binding between RANKL and RANK and is therefore the major inhibitor of osteoclast development and bone resorption [5, 6]. OPG exists as monomer, dimer and RANKL/OPG complexes [1].
An increased ratio of soluble RANKL (sRANKL) to OPG is associated with increased bone turnover and bone loss in adults [4]. Preliminary studies suggest that elevated sRANKL and/or reduced OPG concentrations result in increased bone resorption and reduced bone mass in children suffering from rheumatoid arthritis, systemic lupus erythematodes, and obesity [6,7,8,9,10,11]. However, the interpretation of these studies is hampered by the lack of adequately sized control cohorts, especially since they included boys and girls of different ages and stages of maturation. The development of Lambda-Mu-Sigma (LMS)-based continuous reference percentiles for laboratory parameters allows calculation of patient z-scores and improved data interpretation in clinical practice and studies [12,13,14,15].
To fill the gaps, we established the LMS-based continuous pediatric reference percentiles for sRANKL, OPG and sRANKL/OPG ratio in the HAnnover Reference values for Pediatrics (HARP) study.
Methods
Study design and subjects
HARP, a monocentric cross-sectional study aiming to establish reference values for important laboratory parameters in children, began in 2021. Children aged 0.1–18.0 years were enrolled either from outpatient clinics at University Children’s Hospital, Hannover Medical School, Hannover, Germany, referred for diagnostic work-up, or participated in a study on the effects of a school-based exercise program (only samples at study begin were included) (Fig. 1). Exclusion criteria for this study were: growth retardation, malnutrition, diabetes mellitus, history of fractures, reduced mobility, bone disease, infections (C-reactive protein (CRP) > 5 mg/l), inflammatory or liver disease, anemia (hemoglobin levels below the age-related lower limit), estimated glomerular filtration rate (eGFR) below the age-related normal range, proteinuria (protein to creatinine ratio > 0.2 g/g), tubular dysfunction or medication potentially interfering with bone or mineral metabolism. In this analysis a total of 300 children (166 boys) with a median age of 11.5 years (interquartile range (IQR) 7.6–14.8 years) were included (Table 1). The study protocol was approved by the Ethics Committee of Hannover Medical School and the study was performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all parents/guardians with age-appropriate consent from the children and adolescents.
Sample collection, anthropometric, and laboratory analyses
All children underwent standardized anthropometric evaluation including height/length and weight. Blood samples were obtained between 8:00 and 12:00 am, usually at least 2 h after the last intake of a meal, in parallel with the second morning urine. Samples were stored at -80 °C until assayed. Calcium (Ca), phosphate (Pi), CRP, creatinine (Crea) and 25-hydroxy-vitamin D (25(OH)D) in serum, as well as Ca, Pi and Crea in urine were determined via established automated procedures (Cobas 8000, module c701, Roche Diagnostics, Mannheim, Germany). 25(OH)D levels were subdivided into insufficient and deficient concentrations as previously described [16]. eGFR was calculated by the Schwartz formula [17, 18]. Serum sRANKL (Human Free soluble RANKL, BI-20462, Biomedica Immunoassays) and plasma OPG (Human Osteoprotegerin ELISA, #RD194003200, BioVendor) levels were determined in duplicate by sandwich enzyme-linked immunosorbent assays (ELISA) according to the manufacturer´s protocol using Tecan 96-well plate reader (Tecan infinite M200 PRO). sRANKL and OPG concentrations were quantified with Magellan software (Magellan 7.2 SP1). and the sRANKL/OPG ratio was calculated for every subject. The limit of detection for these assays were 0.01 pmol/L (sRANKL) and 0.03 pmol/L (OPG) with an intra- and inter-assay precision of ≤ 4% and ≤ 3% for sRANKL and ≤ 4.9% and ≤ 9.0% for OPG, respectively.
Statistical analysis
Data is presented as mean ± SD or median (IQR) according to Shapiro–Wilk normality tests. Differences between groups were assessed by unpaired t-test or Mann–Whitney U test, respectively, with two-sided p values and p < 0.05 considered to be statistically significant. Correlation analyses were performed using the Pearson or Spearman correlation coefficients, respectively. All statistical analyses were performed with IBM SPSS Statistics version 27 and GraphPrad Prism version 9. Age and sex-related z-scores for height/length, weight and body mass index (BMI) were calculated using national reference values according to the following formula: z = ((x/M)L-1)/(S \(\times\) L) for L \(\ne\) 0 [19]. Z-scores for serum Ca and Pi, and urinary Ca/Crea and Pi/Crea ratios were calculated using reference values from healthy children [20, 21] according to the following equation [22], POI = parameter of interest, upper = upper limit of range, lower = lower limit of range, SD = standard deviation, and ln = natural log (i.e. Log base e):
-
Step 1: \(PO{I}_{logmean}=\frac{ln\left(upper\right)+ln(lower)}{2}\)
-
Step 2: \(PO{I}_{logSD}=\frac{ln\left(upper\right)-ln(lower)}{4}\)
-
Step 3: \(PO{I}_{z-score}=\frac{ln\left(POI\right)-PO{I}_{logmean}}{PO{I}_{logSD}}\)
LMS-based continuous reference percentiles for sRANKL, OPG, and sRANKL/OPG ratio were created using the open-source software RefCurv 0.4.2 for Windows with generalized additive models for location, scale and shape (GAMLSS) package developed by Winkler et al. [23]. The mathematical method is based on the Box-Cox-Cole-Green distribution (BCCG) and penalized splines in the distribution parameters Lambda (skewness), Mu (median) and Sigma (coefficient of variation) [24,25,26]. The degree of freedom of each penalized spline of L, M and S determines the outcome of the model. A higher degree of freedom results in greater flexibility of the curves. The Bayesian Information Criterion (BIC) was used as a decision support for model selection. The combination of L, M and S with the lowest BIC is assumed the most suitable in the tradeoff between the best fit and complexity regarding the chosen data. The following combinations were used to calculate the percentile curves and LMS values: sRANKL boys: L = 1, M = 2, S = 0 with BIC = -88.7889; sRANKL girls: L = 0, M = 1, S = 0 with BIC = -125.8139; OPG: L = 0, M = 0, S = 0 with BIC = 1032.98; sRANKL/OPG boys: L = 0, M = 2, S = 0 with BIC = -507.0101; sRANKL/OPG girls: L = 0, M = 1, S = 0 with BIC = -439.1746. Normal distribution of residuals including QQ-plots and worm plots were verified as quality control steps for each LMS model computed with RefCurv (Supplemental Figs. 1–5).
Results
Demographic, anthropometric and biochemical characteristics of the HARP cohort
The demographic, anthropometric and biochemical parameters of 300 children (55% boys) enrolled in HARP are summarized in Table 1. The median standardized values for height/length, weight and BMI, serum/urine parameters for mineral metabolism, and eGFR did not differ from healthy children. As expected in this North European population studied at different times of the year many children showed reduced serum 25(OH)D levels (56%).
LMS-based percentiles and LMS values for sRANKL, OPG, and sRANKL/OPG ratio
Both serum concentrations for sRANKL and OPG were negatively associated with age, while sRANKL also associated with sex (Fig. 2a–c, Table 2). In boys, sRANKL percentiles were highest during infancy (0—2 years), followed by a continuous decline until the age of 7 years, and a second peak at 12–13 years of age, the time of expected onset of pubertal growth spurt, to then drop to adult values by the age of 18 years (Fig. 2a, Table 2a). In girls, a continuous slow decline of sRANKL percentiles was noticed from infancy (0—2 years) onwards until the age of 13 years, followed by a rapid decline until adulthood (Fig. 2b, Table 2b). OPG percentiles continuously declined from infancy to adulthood, irrespectively of sex (Fig. 2c, Table 3). The percentiles for sRANKL/OPG ratio paralleled those of sRANKL in both boys and girls (Fig. 2d and e, Table 4).
Correlations of sRANKL and OPG with anthropometric and mineral metabolism parameters
In both boys and girls, serum concentrations of sRANKL correlated with OPG (boys: r = -0.171, p = 0.034; girls: r = -0.365, p < 0.0001) (Fig. 3a and b) and serum phosphate z-scores (boys: r = 0.2216, p = 0.0093; girls: r = 0.2743, p = 0.0044; Fig. 3c and d). OPG concentrations were inversely associated with standardized body weight (r = -0.266, p < 0.0001), BMI (r = -0.239; p < 0.0001) and urinary phosphate to creatinine ratio (r = -0.172; p = 0.0165) (Fig. 3e–g). In contrast, neither absolute nor categorized values for 25(OH)D serum concentrations nor serum/urinary calcium values were significantly associated with serum sRANKL or OPG levels (data not shown).
Discussion
This is the first study establishing LMS-based continuous pediatric reference percentiles for sRANKL, OPG and sRANKL/OPG ratio, which were derived from the HARP cohort. This allows the calculation of standardized patient z-scores to improve assessment and monitoring of bone modeling in children in clinical practice and studies.
In the present study, LMS percentiles for serum sRANKL, OPG and sRANKL/OPG ratio were negatively associated with age, while sRANKL and sRANKL/OPG ratio also associated with sex. Boys, but not girls, showed a second although lower peak for sRANKL and sRANKL/OPG ratio during ages 12–13 years. The strong age-dependence of all parameters assessed, with highest values during infancy, is striking. This most likely represents the physiologically highest growth rates and thus higher bone modeling in infancy compared to childhood and adolescence [3]. A second peak for sRANKL and the sRANKL/OPG ratio was observed in boys at the ages of 12–13, the point of physiological onset of pubertal growth spurt, indicating a high bone modulation with relatively increased bone resorption at this age. This further supports the concept, that increased bone modeling in early puberty, together with the strongly increased gains of height and weight but lag of bone mineral accrual, contributes to a more filigree long bone and explains the observed increased fracture rate in early puberty [27]. In addition, it has been demonstrated that sex hormones regulate RANK and sRANKL expression, possibly leading to an increase in their concentrations during puberty [28]. The absence of a second peak for sRANKL and the sRANKL/OPG ratio during puberty in girls may, at least partly, be due to the fact that girls show less bone mass accrual during puberty and consequently have less bone remodeling than boys during this period [29].
The previously largest pediatric cross-sectional study reporting on sRANKL, OPG and sRANKL/OPG ratio included 259 healthy children aged 1 to 20 years [5]. The authors noted significant associations between sRANKL and categorized values for age, Tanner stage, and BMI z-score. In addition, OPG values were inversely associated with standardized BMI. The comparison of this report with the present study is hampered, since only median and IQR, but no upper and lower limits (97.5th and 2.5th percentiles), are given in this study. In general, however, median and IQR for sRANKL/OPG appeared to be somewhat higher in the present study when compared to the 4 available age cohorts reported by Akhtar Ali et al. whereas median and IQR values for the sRANKL/OPG ratio were comparable. These discrepancies may be due, at least in part, to differences in cohort compositions and/or methodology. For example, Akhtar Ali et al. did not include infants and used very wide age ranges instead of continuous LMS percentiles, as well as a different assay, to assess OPG compared to the present study. Overall, the LMS percentiles for sRANKL, OPG and sRANKL/OPG ratio show a smoother variation with age and splitting between boys and girls, likely reflecting the physiological differences in bone modeling during puberty in boys compared to girls, when compared to the study of Akhtar Ali et al.
Wasilewska et al. investigated sRANKL and OPG values in a cohort of 70 healthy children [1]. They noted significantly higher median sRANKL values in boys compared to girls, irrespective of age, lower values in younger (age < 9 years) compared to older (> 9 years) children, while OPG levels were not associated with age, which is in contrast to the considerably larger-sized studies performed by Akhtar Ali et al. and us. Also in this study, the medians and standard deviations for sRANKL and OPG are somewhat lower compared with the present study, although the same assay for sRANKL was used in both studies. This could be due, at least in part, to the fact that sRANKL levels were undetectable in some patients and/or to the small number of participants included.
Serum sRANKL concentrations were significantly associated with OPG values, irrespective of sex, which supports the concept of strong interrelations within the sRANKL/RANKL/OPG system, which was noted in smaller-sized previous studies [1, 5, 6, 30]. In addition, sRANKL was positively associated with standardized serum phosphate and OPG was inversely associated with standardized urinary phosphate to creatinine ratio in both sexes, suggesting that both high sRANKL and low OPG levels stimulate bone resorption, thereby increasing serum phosphate levels and urinary phosphate excretion, respectively.
We identified an inverse correlation between OPG plasma concentrations and standardized values for body weight and BMI, which is in line with previous studies in healthy as well as obese children and adults [5, 7, 10, 11, 31]. Dimitri et al. investigated OPG plasma levels in healthy lean and obese children and noted that OPG levels were lowest in obese children with a prior fracture, suggesting increased bone resorption in relation to formation in obese children [7]. It has been proposed that obesity may be aggravated by a lack of physical activity, which results in low bone turnover and thus low OPG concentrations. Alternatively, obesity itself may promote osteoclast activity via secretion of adipokines like leptin, resulting in reduced OPG secretion by activation of osteoblast leptin receptors [7].
This study should be considered in the context of its limitations. Firstly, bone marker levels may differ in cohorts of different ethnic background. Due to the composition of the general population in Germany, predominantly Caucasian children were enrolled in HARP. This must be taken into account when using our reference values for children with other ethnic backgrounds. Secondly, RANKL and OPG act at the paracrine level. The determination of serum sRANKL and plasma OPG concentrations was performed using ELISA, which was satisfactory, concerning reproducibility and handling qualities. RANKL concentrations have to be differentiated into total RANKL and freely soluble RANKL. As in most other studies, free soluble RANKL levels were measured [5,6,7, 32]. Another study investigated the total RANKL levels, but specified that it is unknown whether the detected levels and activities of sRANKL are correlated to the membrane-bound protein [30]. Both free soluble and total RANKL levels may be inaccurate because of the lack of information on the tissue source of the measured RANKL concentrations and because of the uncertainty whether circulating RANKL levels represent overall levels or concentrations in specific regions of interest. Moreover, the stability of RANKL and its diurnal fluctuation were not evaluated and it is unclear whether there is an optimal point for sample collection [2]. OPG is present as a free and bound form as RANKL/OPG complexes. The ELISA kit used detects all forms of circulating OPG [30]. Thirdly, bone mass accrual can persist for up to seven years after peak height growth velocity [33]. Thus, the age range used in the present study of 0.1 to 18 years may not be sufficient to represent the entire age-related dynamic of these parameters. Fourthly, we did not evaluate the impact of combined oral contraceptives in female adolescents as they were shown to interact with growth hormone and gonadal steroid hormones [34]. Fifthly, we did not assess Tanner stages in this cross-sectional study and therefore, we could not evaluate the impact of adrenarche and pubarche on the presented reference values in our population.
In conclusion, here we present LMS-based continuous pediatric reference percentiles for sRANKL, OPG and sRANKL/OPG ratio derived from the HARP cohort, that allow calculation of standardized patient z-scores to assess bone modeling in children and adolescents in clinical practice and studies. The observed associations between sRANKL, OPG, and the sRANKL/OPG ratio with age, sex, anthropometric and mineral metabolism parameters underscore the close relationship between bone modeling, growth and maturation in children.
Data availability
Datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.
References
Wasilewska A, Rybi-Szuminska A, Zoch-Zwierz W (2010) Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children. Pediatr Nephrol 25:2067. https://doi.org/10.1007/s00467-010-1583-1
Findlay DM, Atkins GJ (2011) Relationship between serum RANKL and RANKL in bone. Osteoporos Int 22:2597–2602. https://doi.org/10.1007/s00198-011-1740-9
Maggioli C, Stagi S (2017) Bone modeling, remodeling, and skeletal health in children and adolescents: mineral accrual, assessment and treatment. Ann Pediatr Endocrinol Metab 22:1–5. https://doi.org/10.6065/apem.2017.22.1.1
Boyce BF, Xing L (2008) Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473:139–146. https://doi.org/10.1016/j.abb.2008.03.018
Akhtar Ali S, Kang H, Olney R, Ramos-Platt L, Ryabets-Lienhard A, Georgia S, Pitukcheewanont P (2019) Quantifying RANKL and OPG levels in healthy children: A large cross-sectional analysis. Bone 127:215–219. https://doi.org/10.1016/j.bone.2019.06.012
Buzi F, Maccarinelli G, Guaragni B, Ruggeri F, Radetti G, Meini A, Mazzolari E, Cocchi D (2004) Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner’s syndrome and rheumatoid arthritis. Clin Endocrinol 60:87–91. https://doi.org/10.1046/j.1365-2265.2003.01951.x
Dimitri P, Wales JK, Bishop N (2010) Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass. Bone 48:189–196. https://doi.org/10.1016/j.bone.2010.09.034
Lien G, Ueland T, Godang K, Selvaag AM, Førre ØT, Flatø B (2010) Serum levels of osteoprotegerin and receptor activator of nuclear factor -κB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study. Pediatr Rheumatol Online J 8:30. https://doi.org/10.1186/1546-0096-8-30
Ali R, Hammad A, El-Nahrery E, Hamdy N, Elhawary AK, Eid R (2019) Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus. Lupus 28:1233–1242. https://doi.org/10.1177/0961203319867129
Stanik J, Kratzsch J, Landgraf K, Vogel M, Thiery J, Kiess W, Körner A (2019) The bone markers sclerostin, osteoprotegerin, and bone-specific alkaline phosphatase are related to insulin resistance in children and adolescents, independent of their association with growth and obesity. Horm Res Paediatr 91:1–8. https://doi.org/10.1159/000497113
Erol M, BostanGayret O, TekinNacaroglu H, Yigit O, Zengi O, SalihAkkurt M, Tasdemir M (2016) Association of osteoprotegerin with obesity, insulin resistance and non-alcoholic fatty liver disease in children. Iran Red Crescent Med J 18:e41873. https://doi.org/10.5812/ircmj.41873
Lun MX, Gui C, Zhang L, Shang N, Xiao YW, Lv LJ, Huang HL (2021) Application of the LMS method of constructing fetal reference charts: comparison with the original method. J Matern Fetal Neonatal Med 34:395–402. https://doi.org/10.1080/14767058.2019.1608942
Jo BS, Myong JP, Rhee CK, Yoon HK, Koo JW, Kim HR (2018) Reference values for spirometry derived using Lambda, Mu, Sigma (LMS) method in Korean adults: in comparison with previous references. J Korean Med Sci 33:e16. https://doi.org/10.3346/jkms.2018.33.e16
Liu S, Su Z, Pan L, Chen J, Zhao X, Wang L, Zhang L, Su Q, Su H (2023) Pattern of linear growth and progression of bone maturation for girls with early-onset puberty: A mixed longitudinal study. Front Pediatr 11:1056035. https://doi.org/10.3389/fped.2023.1056035
Linden K, Otte F, Winkler C, Laser KT, Goldschmidt F, Breuer J, Herberg U (2022) Atrioventricular coupling in infants and children assessed by three-dimensional echocardiography. J Am Soc Echocardiogr 35:976–984. https://doi.org/10.1016/j.echo.2022.04.014
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine Society (2011) Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930. https://doi.org/10.1210/jc.2011-0385
Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637. https://doi.org/10.1681/asn.2008030287
Schwartz GJ, Work DF (2009) Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 4:1832–1843. https://doi.org/10.2215/CJN.01640309
Neuhauser H, Schienkiewitz A, Schaffrath Rosario A, Dortschy R, Kurth BM (2013) Referenzperzentile für anthropometrische Maßzahlen und Blutdruck aus der Studie zur Gesundheit von Kindern und Jugendlichen in Deutschland (KiGGS). (Reference percentiles for anthropometric measures and blood pressure from the Study on the Health of Children and Adolescents in Germany (KiGGS)). Robert Koch Institut 2:1–129
Matos V, van Melle G, Boulat O, Markert M, Bachmann C, Guignard JP (1997) Urinary phosphate/creatinine, calcium/creatinine, and magnesium/creatinine ratios in a healthy pediatric population. J Pediatr 131:252–257. https://doi.org/10.1016/s0022-3476(97)70162-8
Asgari S, Higgins V, McCudden C, Adeli K (2019) Continuous reference intervals for 38 biochemical markers in healthy children and adolescents: Comparisons to traditionally partitioned reference intervals. Clin Biochem 73:82–89. https://doi.org/10.1016/j.clinbiochem.2019.08.010
Uday S, Shaw NJ, Mughal MZ, Randell T, Högler W, Santos R, Padidela R (2021) Monitoring response to conventional treatment in children with XLH: Value of ALP and Rickets Severity Score (RSS) in a real-world setting. Bone 151:116025. https://doi.org/10.1016/j.bone.2021.116025
Winkler C, Linden K, Mayr A, Schultz T, Welchowski T, Breuer J, Herberg U (2019) RefCurv: A software for the construction of pediatric reference curves. Softw Impacts 6. https://doi.org/10.1016/j.simpa.2020.100040
Cole TJ (1990) LMS method for constructing normalized growth standards. Eur J Clin Nutr 44:45–60
Cole TJ, Green PJ (1992) Smoothing reference centile curves: The lms method and penalized likelihood. Stat Med 11:1305–1319. https://doi.org/10.1002/sim.4780111005
Cole TJ, Freeman JV, Preece MA (1998) British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med 17:407–429
Goulding A (2007) Risk factors for fractures in normally active children and adolescents. Med Sport Sci 51:102–120. https://doi.org/10.1159/000103007
Pan R, Liu Y, Deng H, Dvornyk V (2012) Association analyses suggest the effects of RANK and RANKL on age at menarche in Chinese women. Climacteric 15:75–81. https://doi.org/10.3109/13697137.2011.587556
Stagi S, Cavalli L, Iurato C, Seminara S, Brandi ML, de Martino M (2013) Bone metabolism in children and adolescents: main characteristics of the determinants of peak bone mass. Clin Cases Miner Bone Metab 10:172–179
Wasilewska A, Rybi-Szuminska AA, Zoch-Zwierz W (2009) Serum osteoprotegrin (OPG) and receptor activator of nuclear factor κΒ (RANKL) in healthy children and adolescents. J Pediatr Endocrinol Metab 22:1099–1104. https://doi.org/10.1515/JPEM.2009.22.12.1099
Holecki M, Zahorska-Markiewicz B, Janowska J, Nieszporek T, Wojaczyńska-Stanek K, Żak-Gołąb A, Więcek A (2007) The influence of weight loss on serum osteoprotegerin concentration in obese perimenopausal women. Obesity (Silver Spring) 15:1925–1929. https://doi.org/10.1038/oby.2007.229
Serrano-Piña R, Trujillo-Güiza ML, ScougallVilchis RJ, Layton-Tovar CF, Mendieta-Zerón H (2017) sRANKL and its correlation with metabolic syndrome parameters in children. Int J Paediatr Dent 28:633–640. https://doi.org/10.1111/ipd.12422
Russell M, Breggia A, Mendes N, Klibanski A, Misra M (2011) Growth hormone is positively associated with surrogate markers of bone turnover during puberty. Clin Endocrinol (Oxf) 75:482–488. https://doi.org/10.1111/j.1365-2265.2011.04088.x
Bachrach LK (2020) Hormonal contraception and bone health in adolescents. Front Endocrinol (Lausanne) 11:603. https://doi.org/10.3389/fendo.2020.00603
Acknowledgements
The authors thank the participants who took part in this study. The authors also acknowledged Margit Überheide for technical assistance.
Funding
Open Access funding enabled and organized by Projekt DEAL. This study was supported by Kyowa Kirin, Germany. Kyowa Kirin had no role in the design and conduct of the study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
All procedures performed in studies involving human participants were in accordance with the standards of the institutional Ethics Committee of Hannover Medical School and with the 1964 Helsinki declaration and later amendments or comparable ethical standards.
Consent for publication
All results presented in this article are in aggregate form, and no personally identifiable information was used for this study.
Informed consent
Informed consent was obtained from all individual participants and/or their parent/guardian included in the study.
Conflict of interest
Dieter Haffner and Dirk Schnabel received speaker fees, consultation fees, and research grants from Kyowa Kirin. Helene Tietze, Veronika Pott, Nele Kanzelmeyer, Nima Memaran, Ulrich Baumann, Charlotte Mindermann, Adriana Suhlrie, Jens Drube, Anette Melk, Anibh M. Das, and Maren Leifheit-Nestler declare that they have no conflict of interest.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Tietze, H., Pott, V., Kanzelmeyer, N. et al. LMS-based continuous pediatric reference values for soluble receptor activator of nuclear factor kappa B ligand (sRANKL) and osteoprotegerin (OPG) in the HARP cohort. Osteoporos Int 35, 533–542 (2024). https://doi.org/10.1007/s00198-023-06959-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-023-06959-5